FDA, fast track and Dyn
Dyne Gets FDA Fast-Track Status for Neuromuscular Product Candidate
Dyne Therapeutics received fast-track designation from the Food and Drug Administration for a treatment of myotonic dystrophy type 1, a neuromuscular disease. The Waltham, Mass., developer of biotech treatments for muscle diseases said its DYNE-101 product candidate,
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...
aureus). The FDA grants Fast Track designation to products under development that have the potential to treat or prevent serious conditions and address an unmet medical need. The Fast Track ...
Tips from the experts and the latest fast-track products to help you look and feel your best in minutes. Natural skincare specialist Liz Earle says there is no need for a complicated cleansing ...
Fast Track designation means the FDA will expedite review and development of products aimed at serious conditions, where there is a need for new therapies. It allows for early and frequent ...
the risk that the receipt of Fast Track designation for Emi-Le may not result in a faster development or regulatory review or approval process compared to products considered for approval under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback